Small molecule · Antagonist of serotonin 5-HT2A receptor (HTR2A) and dopamine D2 receptor (DRD2) · developed by Intra-Cellular
ApprovedFDA, Dec 2019
What is Lumateperone?
Lumateperone is an atypical antipsychotic that acts on central serotonin 5-HT2A receptors as an antagonist and on central dopamine D2 receptors as a partial agonist.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 20, 2025). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.